Merck has entered a definitive agreement to acquire biopharmaceutical company Verona Pharma in a deal valued at $10bn.

Merck & Co., Inc. (NYSE:MRK) ranks among the best set-it-and-forget-it stocks to buy. On June 27, TD Cowen maintained its ...

Merck Sharp and Dohme). The issue before the Court is whether Patent Term Extension under 35 U.S.C. § 156 in a reissue patent should be calculated from the original grant date of a patent or ...

He began his career in the pharmaceutical industry in 1996 when he joined Merck, Sharp & Dohme (MSD) at the UK subsidiary, advancing through different roles in the business around the world.

U.S. pharmaceutical firm Merck will purchase U.K.-based Verona Pharma for around $10 billion, the companies said Wednesday.

(RTTNews) - Halozyme Therapeutics (HALO) filed a patent infringement lawsuit against Merck Sharp & Dohme Corp. in U.S. District Court in New Jersey. Halozyme believes the subcutaneous formulation ...

Merck Sharp & Dohme LLC has identified NLRP3 inflammasome inhibitors reported to be useful for the treatment of atherosclerosis, nonalcoholic or metabolic dysfunction-associated steatohepatitis ...

Call 1-800-FDA-1088 to request a reporting form In addition, please provide a copy of all FDA MedWatch forms to: Merck Sharp & Dohme LLC, Rahway, NJ USA by: Fax: 215-616-5677 ...

(Funded by Merck Sharp and Dohme, a subsidiary of Merck; LITESPARK-005 ClinicalTrials.gov number, NCT04195750.) Quick Take. Belzutifan vs. Everolimus for Advanced Renal-Cell Carcinoma.